SAMSUNG BIOLOGICS
207940KOSPI🇰🇷Healthcare · Biotechnology
Last updated: 8h ago
52-Week Range
Company Overview
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Develo
🤖 AI Stock Analysis
📊 Valuation: With a PER of 59.91 and Forward PER of 41.0, the stock appears highly valued relative to current and future earnings. The PBR of 9.89 also suggests a premium valuation compared to its asset value.
💰 Profitability: ROE at 17.59% and ROA at 9.11% indicate good profitability, while net profit margin of 39.16% and operating profit margin of 41.06% demonstrate exceptionally high earnings efficiency.
📈 Growth: (Data not provided)
💵 Dividend: The company has a dividend payout ratio of 0.0%, meaning no dividends are currently distributed.
💬 Summary: The company exhibits strong profitability and sound financial health, driving its growth. However, the high valuation is a factor to consider. An assessment of its long-term growth potential is crucial.
AI-generated reference material. Not investment advice.